Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 16.7%GRADE not reported 0 · 0%Very low 1 · 16.7%Low 4 · 66.7%Moderate 0 · 0%High 0 · 0%

Lower‐dose methylnaltrexone vs higher dose

Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction

Methylnaltrexone lower dose showed no clear difference in laxation response: risk of spontaneous rescue‐free bowel… compared with higher dose (low certainty).

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
RR 0.21 [0.03, 1.41]
2 studies · 135 participants
Low

Lower‐dose methylnaltrexone vs higher dose

Laxation response: risk of spontaneous rescue‐free bowel movements in the medium termb · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction

It is very uncertain whether methylnaltrexone lower dose changes laxation response: risk of spontaneous rescue‐free bowel… compared with higher dose (very low certainty).

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
RR 2.91 [0.82, 10.39]
1 study · 26 participants
Very low

Lower‐dose methylnaltrexone vs higher dose

Laxation response: patient assessment of change in bowel status at the end of trial · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction

Methylnaltrexone lower dose showed no clear difference in laxation response: patient assessment of change in bowel statusgat… compared with higher dose (low certainty).

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
RR 0.98 [0.71, 1.35]
1 study · 102 participants
Low

Lower‐dose methylnaltrexone vs higher dose

Symptoms of opioid withdrawal in the medium term · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction

Methylnaltrexone lower dose showed no clear difference in symptoms of opioid withdrawal in the medium term compared with higher dose (low certainty).

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 102 participants
Low

Lower‐dose methylnaltrexone vs higher dose

Serious adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction

The review found no eligible studies for this question.

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Lower‐dose methylnaltrexone vs higher dose

Adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction

Methylnaltrexone lower dose showed no clear difference in adverse events compared with higher dose (low certainty).

1 finding from 1 review

Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
RR 1 [1, 1]
2 studies · 135 participants
Low